New Patient Appointment or 214-645-8300

MedBlog

All James Brugarolas, M.D., Ph.D.

Cancer

New immunotherapy drug combination is a significant advancement in kidney cancer therapy

A new immunotherapy drug combination has been dubbed a significant advancement in kidney cancer treatment. The combination of ipilimumab and nivolumab can improve outcomes and quality of life. Learn more.

Cancer

The Team That's Doubling Cancer Survival Rates

Cancer

Dr. Brugarolas’ perspective: Treating cancer with a one-two punch